Zynerba Pharmaceuticals (ZYNE) Stock Price, News & Analysis

Company Overview

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.

Key Stats

• Today's Range: $1.30 to $1.30
• 50-Day Range: $1.21 to $1.39
• 52-Week Range: $0.25 to $1.40
• Volume: N/A
• Average Volume: 515,333 shs
• Market Capitalization: $70.12 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ZYNE Stock Analysis - Frequently Asked Questions

How were Zynerba Pharmaceuticals' earnings last quarter?

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) posted its quarterly earnings data on Monday, May, 15th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.19) by $0.02.

When did Zynerba Pharmaceuticals IPO?

Zynerba Pharmaceuticals (ZYNE) raised $42 million in an IPO on Wednesday, August 5th 2015. The company issued 3,000,000 shares at a price of $13.00-$15.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Canaccord Genuity and Oppenheimer & Co. were co-managers.

What other stocks do shareholders of Zynerba Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Zynerba Pharmaceuticals investors own include Canopy Growth (CGC), Cara Therapeutics (CARA), GW Pharmaceuticals (GWPH), NVIDIA (NVDA), Cronos Group (CRON), Meta Platforms (META) and Aurora Cannabis (ACB).

Company Calendar

• Last Earnings: 5/15/2023
• Today: 8/10/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ZYNE
• CIK: 1621443
• Web: www.zynerba.com
• Phone: (484) 581-7505
• Fax: N/A
• Employees: 25
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.80)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$35.04 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -90.03%
• Return on Assets: -72.62%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.43
• Quick Ratio: 3.43

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.01 per share
• Price / Book: 1.29

Miscellaneous

• Outstanding Shares: 53,939,000
• Free Float: 46,905,000
• Market Cap: $70.12 million
• Optionable: Optionable
• Beta: 1.32